Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 31.80
Ask: 32.90
Change: 0.50 (1.54%)
Spread: 1.10 (3.459%)
Open: 32.00
High: 33.00
Low: 32.00
Prev. Close: 32.50
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on strategic investment in Trellus Health

24 Nov 2020 07:00

RNS Number : 2457G
EKF Diagnostics Holdings PLC
24 November 2020
 

 This announcement contains inside informationfor the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Update on strategic investment in Trellus Health

&

Notice of General Meeting

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that a Circular will today be sent to shareholders providing background to, details of and reasons for, a dividend in specie, to facilitate the spin-out of the Company's shareholding in Trellus Health Limited ("Trellus Health") to EKF's shareholders. Trellus Health is a resilience-driven digital health solution for complex chronic conditions, into which EKF made a $5 million investment on the 20 August 2020.

 

On the 20 August, the Company announced that it was the Trellus Health investors' intention, in the future, to conduct initial market soundings to determine the feasibility and timing of an initial public offering (IPO), and the potential admission to trading on the AIM Market of the London Stock Exchange (AIM) for Trellus Health. If an IPO were to take place, the expectation would be for this to be undertaken in 2021.

 

General Meeting

The Company will be hosting a General Meeting ("GM") on Thursday 10 December 2020 at 11 a.m. The purpose of the GM is to seek shareholders' approval to distribute the Company's entire holding of Trellus Health shares, by way of a dividend in specie, to EKF shareholders. The Dividend in Specie is conditional upon, inter alia, the shareholders approving an ordinary resolution at the GM.

 

The value of the Dividend in Specie (the "Value") has not yet been determined and the number of Trellus Health shares that each shareholder will receive has not yet been determined (the "Ratio"). The Directors will determine whether and when the Dividend in Specie occurs and, if they do so, they will then determine the Value and the Ratio and will then declare the Dividend in Specie shortly thereafter. This will be announced to shareholders via a further regulatory announcement.

 

In light of the current UK Government's public health advice in response to the COVID-19 outbreak, including to limit travel and public gatherings, and the likelihood that this advice may remain in place at the time of the GM, the Company requests that no shareholder should plan to attend the GM in person.

 

The Company will provide a facility for shareholders to join the GM either online or telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 11 a.m. on 8 December 2020.

 

The Notice, which is on the Company's website, contains full details of the resolution to be tabled at the GM and should be read before you complete your vote. The Directors consider that the proposed resolution contained in the notice of GM is in the best interests of the Company and shareholders as a whole and unanimously recommend that you vote in favour of it, as they intend to do in respect of their own shareholdings.

 

To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the GM in the post. Instead, shareholders will be able to vote electronically using the link www.signalshares.com. Shareholders will need to log into the Signal Shares account, or register. Proxy votes must be received no later than 11 a.m. on 8 December 2020.

 

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Asset Services, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-executive Chairman

Tel: +44 (0) 29 2071 0570

Julian Baines, CEO

Richard Evans, FD & COO

N+1 Singer

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPPGRAGUPUGBW
Date   Source Headline
19th Sep 20167:00 amRNSAppointment of Joint Broker
13th Sep 20169:09 amRNSHolding(s) in Company
12th Sep 201610:24 amRNSGrant of Options
12th Sep 20167:00 amRNSHalf-year Report
16th Aug 20167:00 amRNSNotice of Results
21st Jul 20168:51 amRNSDirector/PDMR Shareholding
18th Jul 20165:12 pmRNSHolding(s) in Company
18th Jul 20164:06 pmRNSDirector/PDMR Shareholding
15th Jul 20161:44 pmRNSHolding(s) in Company
12th Jul 20161:20 pmRNSHolding(s) in Company
12th Jul 20167:00 amRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSDirectorate Change
6th Jul 20167:00 amRNSTrading Update
27th Jun 20164:00 pmRNSDirector/PDMR Shareholding
24th Jun 20163:41 pmRNSDirector/PDMR Shareholding
22nd Jun 20163:49 pmRNSDirector/PDMR Shareholding
22nd Jun 20163:09 pmRNSHolding(s) in Company
21st Jun 20161:09 pmRNSDirector/PDMR Shareholding
10th Jun 20164:20 pmRNSDirector Dealing
9th Jun 201612:20 pmRNSHolding(s) in Company
2nd Jun 20163:44 pmRNSResults of Placing
2nd Jun 201611:43 amRNSResult of AGM
2nd Jun 20167:01 amRNSProposed Placing
2nd Jun 20167:00 amRNSAGM Statement
27th May 20163:17 pmRNSHolding(s) in Company
25th May 201612:47 pmRNSHolding(s) in Company
9th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20167:00 amRNSLoan redemption update
22nd Apr 20169:22 amRNSNotice of AGM
20th Apr 20164:40 pmRNSSecond Price Monitoring Extn
20th Apr 20164:35 pmRNSPrice Monitoring Extension
20th Apr 201611:54 amRNSDirectorate Change
15th Apr 20163:53 pmRNSNotice of loan redemption
11th Apr 20168:37 amRNSDirectorate Change
8th Apr 20167:00 amRNSDirectorate Change
4th Apr 20167:00 amRNSNotice of Results
22nd Mar 20165:25 pmRNSHolding(s) in Company
21st Mar 20165:52 pmRNSHolding(s) in Company
21st Mar 20165:45 pmRNSHolding(s) in Company
21st Mar 20161:48 pmRNSHolding(s) in Company
17th Mar 20164:40 pmRNSSecond Price Monitoring Extn
17th Mar 20164:35 pmRNSPrice Monitoring Extension
16th Mar 20164:55 pmRNSNotice of Results
3rd Feb 20167:00 amRNSTrading Update
19th Jan 20162:44 pmRNSHolding(s) in Company
18th Jan 20164:35 pmRNSPrice Monitoring Extension
18th Jan 201611:56 amRNSHolding(s) in Company
15th Jan 20163:11 pmRNSHolding(s) in Company
23rd Dec 20157:00 amRNSSale of Selah

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.